Welcome to Pharma Disclosure
This website has been developed as a joint initiative between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and VitalTransformation.com to highlight the industry’s new rules on disclosing financial relationships with doctors and healthcare organisations, follow progress in the implementation and to monitor compliance in the 33 countries involved in the initiative …Read more
January 29th 2015 - Hilton, Rotterdam - 9.30-13.15
This event is part of EFPIA's Responsible Transparency initiative, a public information campaign launched to boost pharmaceutical industry preparedness with complying to new disclosure rules for certain financial and other transfers of value with healthcare professionals and organisations. This event will inform the public on the progress of disclosure on a European and member state level.
September 16th, 12:30 - 14:00 CET (11:30 - 13:00 UK)
In preparation for the implementation of The EFPIA Code outlining the disclosure of transfers of value to healthcare professionals, this webinar is an opportunity to discuss the relationship between practitioners and industry, and how improved transparency will ultimately lead to greater trust and improved patient outcomes.
INFARMA, the Polish association for the innovative pharmaceutical industry, is pleased to announce that a joint position regarding conflict of interest has been adopted by the Regional Chamber of Physicians in Warsaw and INFARMA . […]
EFPIA’s ‘Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations’ has now gone live, with member companies in 33 countries starting to collect data. Representatives of practitioners, patients and the industry met at the end of January to discuss the next steps in implementation.
By Zbigniew Gaciong
Implementing EFPIA’s code on transfers of value involves an inequitable level of disclosure by individual doctors and will leave members of the medical profession in Poland open to media sensation, says Zbigniew Gaciong, Chairman of the Department of Internal Medicine, Hypertension and Vascular Diseases at the Medical University of Warsaw
By Athanasios Exadaktylos
While financial transparency will have an important long term impact, there is potential for misunderstanding of the initiative in the short term, believes Athanasios Exadaktylos, Chairman of Thessaloniki Medical Chamber. It is essential to explain the benefits, Dr Exadaktylos says in this Q&A with pharmadisclosure.eu
by Lode Wigersma
While there is understandable concern in the medical profession that financial disclosure will fuel media sensation, the Dutch experience indicates that showing exactly how much was paid to who, for what, neutralises speculation, says Lode Wigersma, former director of the Royal Dutch Medical Association